BioRestorative Therapies Inc. (BRTX) has released encouraging preliminary data from its Phase 2 trial of BRTX-100, a novel cell-based therapy designed to target areas with low blood flow. The data, collected from the first 10 patients with chronic lumbar disc disease (cLDD), show significant improvement in pain and function after 26 and 52 weeks. This positive outcome, coupled with the absence of serious adverse events, positions BRTX-100 as a potential breakthrough treatment for cLDD.